Your browser is no longer supported. Please, upgrade your browser.
Settings
ALXN Alexion Pharmaceuticals, Inc. daily Stock Chart
ALXN [NASD]
Alexion Pharmaceuticals, Inc.
IndexS&P 500 P/E58.33 EPS (ttm)2.31 Insider Own0.40% Shs Outstand224.00M Perf Week1.76%
Market Cap30.16B Forward P/E19.31 EPS next Y6.97 Insider Trans223.52% Shs Float222.21M Perf Month5.76%
Income521.80M PEG3.21 EPS next Q1.34 Inst Own94.90% Short Float2.28% Perf Quarter15.39%
Sales3.41B P/S8.84 EPS this Y162.90% Inst Trans-2.99% Short Ratio1.69 Perf Half Y3.25%
Book/sh39.62 P/B3.40 EPS next Y24.59% ROA3.90% Target Price160.17 Perf Year1.18%
Cash/sh6.45 P/C20.88 EPS next 5Y18.18% ROE6.00% 52W Range96.18 - 145.41 Perf YTD10.04%
Dividend- P/FCF34.07 EPS past 5Y14.00% ROI4.20% 52W High-8.26% Beta1.44
Dividend %- Quick Ratio2.80 Sales past 5Y31.50% Gross Margin91.50% 52W Low38.70% ATR3.02
Employees3121 Current Ratio3.30 Sales Q/Q-37.30% Oper. Margin21.80% RSI (14)51.28 Volatility1.83% 2.38%
OptionableYes Debt/Eq0.33 EPS Q/Q-21.80% Profit Margin15.30% Rel Volume0.47 Prev Close134.63
ShortableYes LT Debt/Eq0.32 EarningsJul 27 BMO Payout0.00% Avg Volume3.00M Price133.40
Recom1.80 SMA20-1.12% SMA505.44% SMA2007.71% Volume1,409,461 Change-0.91%
Aug-17-17Initiated Evercore ISI In-line $137
Jul-28-17Upgrade Oppenheimer Perform → Outperform
May-25-17Upgrade Morgan Stanley Equal-Weight → Overweight
May-23-17Downgrade JP Morgan Overweight → Neutral
Mar-30-17Initiated UBS Buy $138
Mar-02-17Initiated Instinet Buy $148
Feb-17-17Reiterated RBC Capital Mkts Outperform $187 → $177
Dec-22-16Reiterated RBC Capital Mkts Outperform $188 → $187
Dec-15-16Initiated Oppenheimer Perform
Dec-13-16Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-03-16Initiated Deutsche Bank Buy $164
Oct-28-16Upgrade Goldman Neutral → Buy
Oct-28-16Upgrade FBR & Co. Underperform → Mkt Perform $92 → $130
Oct-28-16Reiterated Wedbush Neutral $132 → $135
Sep-23-16Initiated Wedbush Neutral $132
Sep-16-16Reiterated FBR & Co. Underperform $82 → $92
Sep-15-16Initiated FBR & Co. Underperform $82
Jul-29-16Reiterated Stifel Buy $195 → $182
Jul-29-16Reiterated Barclays Equal Weight $165 → $150
Jul-13-16Reiterated SunTrust Buy $220 → $197
Aug-18-17 08:48AM  Horizon Pharma (HZNP) Soars: Stock Adds 10.5% in Session Zacks
Aug-17-17 06:33PM  Seattle Genetics' Adcetris Granted Priority Review by FDA Zacks
06:26PM  Novo Nordisk's Semaglutide Shows Remarkable Results in Study Zacks
08:03AM  See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc. Markit
Aug-16-17 05:44PM  Spectrum (SPPI) Initiates Phase II Study for Cancer Drug Zacks
05:18PM  Shire Files Marketing Application for Lifitegrast in Europe Zacks
09:35AM  Update in Lawsuit for Investors in NASDAQ: ALXN Shares Against Alexion Pharmaceuticals, Inc. Announced by Shareholders Foundation ACCESSWIRE
08:48AM  MiMedx Group (MDXG) in Focus: Stock Moves 6.1% Higher Zacks
08:03AM  See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc. Markit
Aug-15-17 04:05PM  Alexion Receives Three New U.S. Patents for Soliris® (eculizumab), Extending Patent Protection Into 2027 Business Wire
03:17PM  ETFs with exposure to Alexion Pharmaceuticals, Inc. : August 15, 2017 Capital Cube
Aug-14-17 09:32AM  Regeneron vs. Alexion: Which Stock is a Better Pick Post Q2 Earnings? Zacks
08:15AM  Editas Medicine (EDIT) Looks Good: Stock Moves Up 11.3% Zacks
Aug-13-17 07:01AM  Edited Transcript of ALXN earnings conference call or presentation 27-Jul-17 2:00pm GMT Thomson Reuters StreetEvents
Aug-12-17 08:03AM  See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc. Markit
Aug-11-17 01:25PM  Call of the week: Best stocks for a dollar bear market Yahoo Finance
01:13PM  Call of the week: best stocks for a dollar bear market Yahoo Finance Video
08:42AM  Forget Teva (TEVA), Buy These 4 Drug Stocks Instead Zacks
08:30AM  Implied Volatility Surging for Alexion Pharmaceuticals (ALXN) Stock Options Zacks
Aug-10-17 09:06AM  New Patients and Alexion Pharmaceuticals Metabolic Franchise Market Realist
08:04AM  IHS Markit Score downgrades Alexion Pharmaceuticals Inc to 60 out of 100, ranking positively in only one out of three available IHS Markit categories. Markit
07:36AM  Alexion Pharmaceuticals Expects Robust Revenue for Soliris Market Realist
06:30AM  Alexion and Sema4 Partner in Rare Disease Diagnostics and Systems Biology Business Wire
Aug-09-17 10:37AM  Alexion Pharmaceuticals: Modest Growth Projections Market Realist
09:08AM  Alexion Pharmaceuticals Raised 2017 Earnings Guidance Market Realist
08:03AM  See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc. Markit
07:40AM  Alexion Pharmaceuticals Raised Its Revenue Guidance for 2017 Market Realist
Aug-08-17 04:58PM  The Key Reason Alexion Pharmaceuticals, Inc. Vaulted 13% Higher in July Motley Fool
04:52PM  Analyst Recommendations for Alexion Pharmaceuticals in August Market Realist
09:45AM  For Vertex Pharmaceuticals, Can One Billion-Dollar Breakthrough Beget Another? Forbes
09:25AM  Forget Bayer, Buy These 3 Drug Stocks Instead Zacks
Aug-03-17 07:40AM  Featured Company News - US Oncology Research and Epizyme Establish Collaboration to Identify Non-Hodgkin Lymphoma Patients with EZH2 Mutations ACCESSWIRE
Aug-02-17 09:23AM  New Strong Buy Stocks for August 2nd Zacks
Aug-01-17 12:30PM  Stephanie Link: here's what to buy at record highs CNBC
11:07AM  Alexion Pharmaceuticals, Inc. :ALXN-US: Earnings Analysis: Q2, 2017 By the Numbers : August 1, 2017 Capital Cube
12:26AM  3 ETFs to Watch Out for on Biotech Earnings Zacks
Jul-28-17 01:24AM  Alexion tops Street 2Q forecasts Associated Press
Jul-27-17 12:22PM  Alexion: Thank You For Your Patience? Barrons.com
11:20AM  Alexion cuts ties with two Cambridge biotechs in reorganization American City Business Journals
11:03AM  Alexion (ALXN) Tops Q2 Earnings & Revenues, Ups 2017 View Zacks
10:27AM  AstraZeneca Beats, But Stock Dives On Drug Failure; 4 More Report Investor's Business Daily
09:46AM  Alexion posts higher Q2 earnings on strong Soliris sales Reuters
09:29AM  Alexion Spikes on Q2 Earnings Blowout Providing Positive Signs for Rest of Sector -Biotech Movers TheStreet.com
08:40AM  Investor Network: Alexion Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
08:34AM  Alexion (ALXN) Tops Q2 Earnings, Sales; Shares Up Zacks
06:30AM  Alexion Reports Second Quarter 2017 Results Business Wire
Jul-26-17 09:37AM  Biotech Stocks Jul27 Q2 Earnings Roster: BMY, CELG & ALXN Zacks
08:55AM  Why Alexion Pharmaceuticals (ALXN) Might Surprise This Earnings Season Zacks
Jul-25-17 05:02PM  Amgen Topples After Increased Forecast Still Lags Some Views Investor's Business Daily
Jul-24-17 12:07PM  Biogen Earnings Preview: Analysis Investopedia
Jul-21-17 04:14PM  Biotechs On A Hot Streak, And Could Be 'Cooking With Gas' Investor's Business Daily
09:42AM  Are Options Traders Betting on a Big Move in Alexion Pharmaceuticals (ALXN) Stock? Zacks
Jul-20-17 11:31AM  Is a Beat in Store for Alexion (ALXN) this Earnings Season? Zacks
Jul-19-17 02:08PM  Robbins Arroyo LLP Is Investigating the Officers and Directors of Alexion Pharmaceuticals, Inc. (ALXN) on Behalf of Shareholders Business Wire
Jul-17-17 03:41PM  Alexion May Report A Weak Quarter, But The Stock's Still A Buy: Instinet Barrons.com
11:15AM  [$$] Biotechs in Focus Ahead of Earnings Barrons.com
Jul-13-17 09:46AM  Biotech 2Q17: It's Mostly all Gravy Barrons.com
Jul-11-17 06:50PM  Cramer's lightning round: Companies that do this are too desperate for me CNBC
10:00AM  Alexion to Report Second Quarter 2017 Results and Strategic Update on Thursday, July 27, 2017 Business Wire
Jul-10-17 09:07AM  What Analysts Recommend for BioMarin Pharmaceuticals Market Realist
Jul-09-17 08:34AM  3 Stocks With Huge Business Advantages Motley Fool
Jul-07-17 04:35PM  Alexion Investigation Believed to Have 'Minimal Impact' TheStreet.com
11:58AM  Alexion Pharmaceuticals: Nothing to See Here? Barrons.com
09:40AM  Biotech Movers: Alexion, Arena, Novavax TheStreet.com
09:06AM  Alexion Reportedly Being Investigated by HHS, Shares Slip Zacks
09:05AM  The Market In 5 Minutes Benzinga
Jul-06-17 05:51PM  Alexion Pharma Stock Dives On Report It's Under Federal Scrutiny Investor's Business Daily
05:37PM  Alexion Pharmaceuticals reportedly under investigation by HHS CNBC
03:56PM  Alexion stock drops 3.6% on Bloomberg report that it's under investigation MarketWatch
03:44PM  Alexion shares down amid HHS investigation CNBC Videos
03:05PM  Alexion Says U.S. Health Inspector General Is Part of DOJ Probe Bloomberg
Jul-05-17 04:00AM  Alexion Reaches Funding Agreement with NICE and NHS England for Strensiq® (asfotase alfa) for Patients with Pediatric-onset Hypophosphatasia (HPP) Business Wire
Jul-03-17 09:02AM  3 Best-Performing Stocks in June Motley Fool
Jun-30-17 02:30PM  Biogen: Insiders Are Buying. Should You Be Too? Barrons.com
Jun-28-17 03:44PM  2 Fastest Growing Biotech Stocks Motley Fool
12:39PM  Where to find value in health-care stocks ahead of Senate... CNBC Videos
Jun-27-17 04:24PM  Here's Why Ra Pharmaceuticals Inc. Tumbled as Much as 32% Today Motley Fool
Jun-26-17 07:26AM  3 Top Stocks on Sale This Summer Motley Fool
Jun-23-17 08:00AM  Alexion Receives Positive CHMP Opinion for Soliris® (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG) in the European Union Business Wire
Jun-21-17 02:18PM  Biotech Insider Just Loaded Up $234 Million Worth the Stock TheStreet.com
12:05PM  Here are the biotech stocks the traders are buying CNBC Videos
10:35AM  Amgen: In Defense of A Pipeline Barrons.com
08:00AM  Today's Research Reports on Stocks to Watch: Regeneron Pharmaceuticals and Alexion Pharmaceuticals Accesswire
07:57AM  Food & pharma in the trader blitz CNBC Videos
Jun-20-17 01:03PM  UPDATE: Alexion Pharma: Its CEO Really Likes Its Stock! Barrons.com
11:36AM  Story Stocks from Briefing.com Briefing.com
09:09AM  Morning Movers: Tesla Rises, Chipotle Slumps, Lennar Jumps Barrons.com
Jun-19-17 11:11AM  Biogen: "The Underperformance Stops Here" Barrons.com
Jun-16-17 04:40PM  Alexion Pharmaceuticals, Inc. Value Analysis (NASDAQ:ALXN) : June 16, 2017 Capital Cube
Jun-15-17 02:00PM  Alexion Has a Savior Complex Bloomberg
10:07AM  Company News for June 15, 2017 Zacks
08:13AM  Alexion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ALXN-US : June 15, 2017 Capital Cube
08:02AM  Why Alexion's Gain In the C-Suite Doesn't Bode Well For Biogen Takeout Prospects TheStreet.com
08:00AM  Today's Research Reports on Stocks to Watch: Epizyme and Alexion Pharmaceuticals Accesswire
12:20AM  [$$] Alexions Housecleaning Should Continue to Pay Off The Wall Street Journal
Jun-14-17 05:46PM  The Hot Stock: Alexion Pharmaceuticals Jumps 9.3% Barrons.com +9.26%
05:02PM  What Happened in the Stock Market Today Motley Fool
04:16PM  Is Defecting CFO A Glutton For Punishment By Moving To Alexion? Investor's Business Daily
04:16PM  Alexion Stock Soars After It Poaches Biogen CFO Investopedia
02:02PM  [$$] Alexion Even Stronger After Adding Biogen CFO Barrons.com
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. Further, it develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; SBC-103, which is in Phase I/II clinical trials for the treatment of metabolic disorders; ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; and ALXN 1210, which is in Phase I clinical trials to evaluate subcutaneous delivery. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem's proprietary drug discovery engine; and Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for the development and commercialization of Moderna's messenger RNA therapeutics to treat rare diseases. The company was founded in 1992 and is headquartered in New Haven, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Veneman Ann MDirectorJul 31Sale137.7470096,4186,315Aug 02 05:18 PM
BAKER BROS. ADVISORS LPDirectorJun 15Buy117.33656,38777,012,4917,645,906Jun 16 04:04 PM
COUGHLIN CHRISTOPHER JDirectorJun 15Buy117.102,000234,2006,333Jun 16 04:55 PM
PARVEN ALVIN SDirectorJun 15Sale116.7883597,5117,568Jun 16 04:54 PM
BAKER BROS. ADVISORS LPDirectorJun 14Buy116.321,348,955156,915,4447,317,906Jun 16 04:03 PM
BAKER BROS. ADVISORS LPDirectorJun 14Buy118.004,392518,2567,321,850Jun 16 04:04 PM
HANTSON LUDWIGCEOJun 14Buy116.7210,0001,167,20038,725Jun 19 05:21 PM
O'Neill JulieEVP. Global OperationsMar 02Sale133.8065187,10437,864Mar 06 06:03 PM
Carmichael ClareEVP, Chief HR OfficerMar 01Sale132.5040453,53039,161Mar 01 07:44 PM
MACKAY MARTINEVP & Global Head of R&DMar 01Sale132.5037049,02550,688Mar 01 07:45 PM
Wagner Heidi LSVP, Global Government AffairsMar 01Sale132.5015620,67029,010Mar 01 07:44 PM
BELL LEONARDDirectorMar 01Sale132.501,240164,300390,670Mar 01 07:44 PM
Moriarty John BEVP & General CounselMar 01Sale132.5028237,36544,672Mar 01 07:46 PM
Moriarty John BEVP & General CounselFeb 28Sale131.71910119,85644,954Mar 01 07:46 PM
BELL LEONARDDirectorFeb 28Sale131.712,738360,622391,910Mar 01 07:44 PM
Wagner Heidi LSVP, Global Government AffairsFeb 28Sale131.7048063,21629,166Mar 01 07:44 PM
O'Neill JulieEVP. Global OperationsFeb 28Sale131.7066487,44931,015Mar 01 07:46 PM
Miller EdwardSVP, Chief Compliance OfficerFeb 28Sale131.7033043,46114,884Mar 01 07:45 PM
MACKAY MARTINEVP & Global Head of R&DFeb 28Sale131.7062582,31338,258Mar 01 07:45 PM
Thiel CarstenEVP, Chief Commercial OfficerFeb 28Sale131.013,783495,61133,860Mar 06 06:03 PM
Carmichael ClareEVP, Chief HR OfficerFeb 28Sale131.71915120,51533,065Mar 01 07:44 PM
Carmichael ClareEVP, Chief HR OfficerFeb 27Sale131.20860112,83233,980Mar 01 07:44 PM
MACKAY MARTINEVP & Global Head of R&DFeb 27Sale131.20860112,83238,883Mar 01 07:45 PM
Miller EdwardSVP, Chief Compliance OfficerFeb 27Sale131.2026034,11215,214Mar 01 07:45 PM
O'Neill JulieEVP. Global OperationsFeb 27Sale131.20910119,39231,679Mar 01 07:46 PM
Wagner Heidi LSVP, Global Government AffairsFeb 27Sale131.2035846,97029,646Mar 01 07:44 PM
Moriarty John BEVP & General CounselFeb 27Sale131.2061280,29445,864Mar 01 07:46 PM
Thiel CarstenEVP, Chief Commercial OfficerFeb 27Sale131.20719,31530,197Mar 01 07:45 PM
BELL LEONARDDirectorFeb 09Sale126.8424631,203394,648Feb 10 06:05 PM
Moriarty John BEVP & General CounselFeb 09Sale126.8416721,18246,476Feb 10 06:05 PM
MACKAY MARTINEVP & Global Head of R&DFeb 09Sale126.8421727,52439,743Feb 10 06:05 PM
Carmichael ClareEVP, Chief HR OfficerFeb 09Sale126.8416721,18234,840Feb 10 06:05 PM
Wagner Heidi LSVP, Global Government AffairsFeb 07Sale128.0922228,43630,004Feb 08 04:38 PM
BELL LEONARDDirectorFeb 07Sale128.091,010129,371394,894Feb 08 04:40 PM
Moriarty John BEVP & General CounselFeb 07Sale128.0913517,29246,643Feb 08 04:40 PM
Carmichael ClareEVP, Chief HR OfficerFeb 07Sale128.0916621,26335,007Feb 08 04:40 PM
Carmichael ClareEVP, Chief HR OfficerFeb 06Sale125.703,404427,87235,173Feb 08 04:40 PM
MACKAY MARTINEVP & Global Head of R&DFeb 06Sale125.702,728342,90439,960Feb 08 04:39 PM
Thiel CarstenEVP, Chief Commercial OfficerFeb 06Sale125.6916520,73930,268Feb 08 04:39 PM
Miller EdwardSVP, Chief Compliance OfficerFeb 06Sale125.701,045131,35715,474Feb 08 04:39 PM
Moriarty John BEVP & General CounselFeb 06Sale125.693,403427,73946,778Feb 08 04:40 PM
O'Neill JulieEVP. Global OperationsFeb 06Sale125.692,795351,30432,589Feb 08 04:40 PM
BELL LEONARDDirectorFeb 06Sale125.697,715969,728395,904Feb 08 04:40 PM
Wagner Heidi LSVP, Global Government AffairsFeb 06Sale125.691,710214,93530,226Feb 08 04:38 PM
BELL LEONARDDirectorJan 10Option Exercise22.901002,290403,719Jan 13 04:36 PM
BELL LEONARDDirectorJan 10Sale144.9910014,499403,619Jan 13 04:36 PM
BELL LEONARDDirectorJan 09Option Exercise22.904,853111,134408,472Jan 09 05:21 PM
BELL LEONARDDirectorJan 09Sale144.9033448,397403,285Jan 09 05:21 PM
BELL LEONARDDirectorJan 09Sale144.934,853703,345403,619Jan 09 05:21 PM
PARVEN ALVIN SDirectorJan 05Option Exercise54.2620,1661,094,30426,539Jan 09 05:21 PM
BELL LEONARDDirectorJan 05Option Exercise22.9034,210783,409438,497Jan 09 05:21 PM
BELL LEONARDDirectorJan 05Sale137.4066891,783403,619Jan 09 05:21 PM
BELL LEONARDDirectorJan 05Sale137.5334,2104,704,730404,287Jan 09 05:21 PM
PARVEN ALVIN SDirectorJan 05Sale136.862,493341,2023,880Jan 09 05:21 PM
PARVEN ALVIN SDirectorJan 05Sale138.5420,1662,793,7526,373Jan 09 05:21 PM
Moriarty John BEVP & General CounselDec 12Sale118.611,044123,82950,181Dec 13 06:24 PM
Thiel CarstenEVP, Chief Commercial OfficerDec 09Sale130.002,308300,04030,433Dec 13 06:24 PM
Wagner Heidi LSVP, Global Government AffairsNov 14Sale115.10596,79131,936Nov 16 06:00 PM
BELL LEONARDDirectorNov 04Option Exercise22.9036,649839,262440,936Nov 07 07:44 PM
BELL LEONARDDirectorNov 04Sale142.4066895,123404,287Nov 07 07:44 PM
BELL LEONARDDirectorNov 04Sale140.3436,6495,143,377404,287Nov 07 07:44 PM
BELL LEONARDDirectorOct 31Option Exercise22.901,30029,770406,589Nov 02 07:22 PM
BELL LEONARDDirectorOct 31Sale135.3733445,214404,955Nov 02 07:22 PM
BELL LEONARDDirectorOct 31Sale135.281,300175,864405,289Nov 02 07:22 PM
Thiel CarstenEVP, Chief Commercial OfficerOct 14Sale120.284,584551,36432,741Oct 18 06:29 PM
Wagner Heidi LSVP, Global Government AffairsOct 03Sale122.4112014,68931,995Oct 05 05:25 PM
Thiel CarstenEVP, Chief Commercial OfficerOct 03Sale122.41293,55037,325Oct 05 05:25 PM
Thiel CarstenEVP, Chief Commercial OfficerSep 13Sale129.003,000387,00037,354Sep 14 04:34 PM
Thiel CarstenEVP, Chief Commercial OfficerSep 12Sale124.2022527,94540,354Sep 14 04:34 PM
Miller EdwardSVP, Chief Compliance OfficerSep 09Sale128.3236747,09316,519Sep 09 06:23 PM
Thiel CarstenEVP, Chief Commercial OfficerSep 06Sale125.941,000125,94040,579Sep 08 04:33 PM
O'Neill JulieEVP. Global OperationsSep 02Sale126.2965082,08935,384Sep 02 05:11 PM
Carmichael ClareEVP, Chief HR OfficerAug 30Sale127.761,000127,76038,577Sep 01 04:57 PM
PARVEN ALVIN SDirectorAug 22Option Exercise18.0115,000270,15021,373Aug 24 05:33 PM
PARVEN ALVIN SDirectorAug 22Sale136.5315,0002,047,9506,373Aug 24 05:33 PM